🇺🇸 FDA

Company profile · Sponsor

Gedeon

Gedeon Richter Plc.

E524E6D · EMA pharma EU
Pipeline
2
Drugs
0
Patents
0

Quick answer

Gedeon (E524E6D) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E524E6D
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (2)

Search pipeline →

  1. Cariprazine 0.5 mg capsules, hard, Reagila 6 mg hard capsules, Reagila 4.5 mg hard capsules, Reagila 3 mg hard capsules, Reagila 1.5 mg hard capsules

    Gedeon

    Adolescent patient (13-17 years of age) with Schizophrenia

    phase 3 small molecule active

    1 trial

  2. Reagila 1.5 mg hard capsules, For the purpose of the clinical study a placebo formulation was prepared using the same white hard gelatine capsule shell., Reagila 3 mg hard capsules, Cariprazine 0.5 mg capsules, hard, Reagila 4.5 mg hard capsules

    Gedeon

    Adolescent Patients (13 to 17 years of age) with Schizophrenia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Gedeon?

Gedeon (E524E6D) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 2 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Gedeon sponsor?

We track 2 ClinicalTrials.gov-linked programs for Gedeon, including Cariprazine 0.5 mg capsules, hard, Reagila 6 mg hard capsules, Reagila 4.5 mg hard capsules, Reagila 3 mg hard capsules, Reagila 1.5 mg hard capsules and 1 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Gedeon company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.